Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1990 2
1991 4
1992 1
1993 1
1995 2
1997 2
1999 2
2000 3
2002 2
2003 7
2004 8
2005 6
2006 3
2007 10
2008 2
2009 7
2010 14
2011 14
2012 27
2013 18
2014 21
2015 31
2016 46
2017 37
2018 41
2019 44
2020 73
2021 88
2022 37
Text availability
Article attribute
Article type
Publication date

Search Results

486 results
Results by year
Filters applied: . Clear all
Page 1
Phytochemistry of Cannabis sativa L.
ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. ElSohly MA, et al. Prog Chem Org Nat Prod. 2017;103:1-36. doi: 10.1007/978-3-319-45541-9_1. Prog Chem Org Nat Prod. 2017. PMID: 28120229 Review.
Besides delta(9)-THC, there are also non-psychoactive cannabinoids with several medicinal functions, such as cannabidiol (CBD), cannabichromene (CBC), and cannabigerol (CBG), along with other non-cannabinoid constituents belonging to diverse classes of natural products. .. …
Besides delta(9)-THC, there are also non-psychoactive cannabinoids with several medicinal functions, such as cannabidiol (CBD), canna …
UHPLC-MS/MS analysis of cannabidiol metabolites in serum and urine samples. Application to an individual treated with medical cannabis.
Pichini S, Malaca S, Gottardi M, Pérez-Acevedo AP, Papaseit E, Perez-Maña C, Farré M, Pacifici R, Tagliabracci A, Mannocchi G, Busardò FP. Pichini S, et al. Talanta. 2021 Feb 1;223(Pt 2):121772. doi: 10.1016/j.talanta.2020.121772. Epub 2020 Oct 14. Talanta. 2021. PMID: 33298281
We developed and validated a method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) for quantifying cannabidiol (CBD) and its metabolites, cannabidiol-7-oic acid (7-COOH-CBD), 7- hydroxycannabidiol …
We developed and validated a method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS …
Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review.
Balachandran P, Elsohly M, Hill KP. Balachandran P, et al. J Gen Intern Med. 2021 Jul;36(7):2074-2084. doi: 10.1007/s11606-020-06504-8. Epub 2021 Jan 29. J Gen Intern Med. 2021. PMID: 33515191 Review.
Cannabidiol, a non-intoxicating phytocannabinoid, has potential therapeutic effects over a broad range of disorders. ...
Cannabidiol, a non-intoxicating phytocannabinoid, has potential therapeutic effects over a broad range of disorders. ...
Current application of cannabidiol (CBD) in the management and treatment of neurological disorders.
Fiani B, Sarhadi KJ, Soula M, Zafar A, Quadri SA. Fiani B, et al. Neurol Sci. 2020 Nov;41(11):3085-3098. doi: 10.1007/s10072-020-04514-2. Epub 2020 Jun 16. Neurol Sci. 2020. PMID: 32556748 Review.
Cannabidiol (CBD), which is nonintoxicating pharmacologically relevant constituents of Cannabis, demonstrates several beneficial effects. ...While recent FDA-approved prescription drugs have demonstrated safety, efficacy, and consistency enough for regulatory approval in s …
Cannabidiol (CBD), which is nonintoxicating pharmacologically relevant constituents of Cannabis, demonstrates several beneficial effe …
UHPLC-MS/MS Analysis of Cannabidiol and Its Metabolites in Serum of Patients with Resistant Epilepsy Treated with CBD Formulations.
Malaca S, Gottardi M, Pigliasco F, Barco S, Cafaro A, Amadori E, Riva A, Marcenaro M, Striano P, Cangemi G, Pacifici R, Pichini S, Busardò FP. Malaca S, et al. Pharmaceuticals (Basel). 2021 Jun 29;14(7):630. doi: 10.3390/ph14070630. Pharmaceuticals (Basel). 2021. PMID: 34209666 Free PMC article.
Cannabidiol (CBD) is a promising therapeutic agent with analgesic, myorelaxant, and anti-epileptic actions. ...We herein report for the first time a newly developed and validated method using ultra-high-performance liquid chromatography coupled with tandem mass spectrometr …
Cannabidiol (CBD) is a promising therapeutic agent with analgesic, myorelaxant, and anti-epileptic actions. ...We herein report for t …
Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1.
Casares L, García V, Garrido-Rodríguez M, Millán E, Collado JA, García-Martín A, Peñarando J, Calzado MA, de la Vega L, Muñoz E. Casares L, et al. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5. Redox Biol. 2020. PMID: 31518892 Free PMC article.
Cannabidiol (CBD) is a major non-psychotropic phytocannabinoid that attracted a great attention for its therapeutic potential against different pathologies including skin diseases. ...Herein we characterized at the molecular level the effects of CBD on primary human kerati …
Cannabidiol (CBD) is a major non-psychotropic phytocannabinoid that attracted a great attention for its therapeutic potential against …
Cannabinoids for Treatment of MS Symptoms: State of the Evidence.
Rice J, Cameron M. Rice J, et al. Curr Neurol Neurosci Rep. 2018 Jun 19;18(8):50. doi: 10.1007/s11910-018-0859-x. Curr Neurol Neurosci Rep. 2018. PMID: 29923025 Review.
This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the use of cannabinoids for treating spasticity and pain associated with multiple sclerosis (MS), and a discussion of possible dosing regimens bas …
This paper provides an overview of the available cannabinoid-based formulations, a summary of the highest quality evidence for the use of ca …
Cannabis and multiple sclerosis.
Fragoso YD, Carra A, Macias MA. Fragoso YD, et al. Expert Rev Neurother. 2020 Aug;20(8):849-854. doi: 10.1080/14737175.2020.1776610. Epub 2020 Jun 18. Expert Rev Neurother. 2020. PMID: 32515670 Review.
INTRODUCTION: Patients with multiple sclerosis (MS) may suffer from spasticity and pain during their disease course. ...There is no scientific evidence that smoking marijuana can be beneficial to patients with MS....
INTRODUCTION: Patients with multiple sclerosis (MS) may suffer from spasticity and pain during their disease course. ...There is no s …
A Critical Review of the Role of the Cannabinoid Compounds Δ9-Tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD) and their Combination in Multiple Sclerosis Treatment.
Jones É, Vlachou S. Jones É, et al. Molecules. 2020 Oct 25;25(21):4930. doi: 10.3390/molecules25214930. Molecules. 2020. PMID: 33113776 Free PMC article. Review.
Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the symptoms associated with the disease. In line with this, Sativex, a synthetic combination of cannabidiol (CBD) and delta(9)-tetrahydrocannabinol (delta(9)-THC) has been approved to …
Many people with MS (pwMS) use unregulated cannabis or cannabis products to treat the symptoms associated with the disease. In line w …
Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome.
Al-Ghezi ZZ, Busbee PB, Alghetaa H, Nagarkatti PS, Nagarkatti M. Al-Ghezi ZZ, et al. Brain Behav Immun. 2019 Nov;82:25-35. doi: 10.1016/j.bbi.2019.07.028. Epub 2019 Jul 26. Brain Behav Immun. 2019. PMID: 31356922 Free PMC article.
Currently, a combination of marijuana cannabinoids including delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is used as a drug to treat muscle spasticity in patients with Multiple Sclerosis (MS). Because these cannabinoids can also suppress inflammation, it …
Currently, a combination of marijuana cannabinoids including delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) is used as a dr …
486 results